NCT00903747View on ClinicalTrials.gov

Thorough Corrected QT Interval (QTc) Study To Evaluate Possible Effects of Prucalopride on ECG Parameters

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

April 30, 2009

Study Completion Date

May 31, 2009

Conditions
Constipation
Interventions
DRUG

prucalopride

2-10 mg prucalopride

DRUG

moxifloxacin

400 mg moxifloxacin (Group 2a)

DRUG

placebo

placebo (Group 2b)

Sponsors

Lead Sponsor

Movetis
All Listed Sponsors
lead

Movetis

INDUSTRY